Changes to the SciBase Management team
Fredrik Goldkuhl, head of Product Development and member of the Group management team has decided to leave SciBase in August of this year. David Melin will replace Fredrik in the management team and as head of product development.
- During Fredrik’s 11 years at SciBase the Company has undergone major changes from a Company with an idea in an early development phase to now having Nevisense established on a number of European markets and in the final stages of a US approval process. I would like to take the opportunity to thank Fredrik for his great commitment to SciBase and wish him all the best in his new role, says Simon Grant, CEO SciBase.
David Melin has been appointed as his replacement and as new head of product development. David joined SciBase in 2013 and has worked primarily with product development within hardware and system design. David holds a degree of M.Sc. in Mechanical Engineering focusing on Mechatronics from the Royal Institute of Technology, Stockholm.
- David has been a key member of our product development team and has played a central role in the development of our core Nevisense product. He has also driven much of the ongoing development of our new applications and our next generation product platform. I congratulate David on his new role and look forward to working closely with him in the future, says Simon Grant.
For further information please visit www.scibase.com or contact:
Simon Grant, CEO
Tel: +46 72 887 43 99
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 CET on June 13, 2017.
About Skin Cancer
Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.